An integrated prognostic model for diffuse large B-cell lymphoma treated with immunochemotherapy

被引：1

作者：

Rodriguez, Marta ^{[1
,2
]}

Alonso-Alonso, Ruth ^{[1
,2
]}

Fernandez-Miranda, Ismael ^{[3
]}

Mondejar, Rufino ^{[2
,4
]}

Cereceda, Laura ^{[1
,2
]}

Trascasa, Alvaro ^{[1
]}

Conceicao, Anabel Antonio-Da ^{[1
]}

Borregon, Jennifer ^{[1
]}

Gato, Lucia ^{[1
]}

Tomas-Roca, Laura ^{[1
]}

Barcena, Carmen ^{[5
]}

Iglesias, Begona ^{[6
]}

Climent, Fina ^{[7
]}

Gonzalez-Barca, Eva ^{[8
]}

Camacho, Francisca Inmaculada ^{[9
]}

Mayordomo, Empar ^{[10
]}

Olmedilla, Gabriel ^{[11
]}

Gomez-Prieto, Pilar ^{[12
]}

Castro, Yolanda ^{[13
]}

Serrano-Lopez, Juana ^{[14
]}

Sanchez-Garcia, Joaquin ^{[15
]}

Montes-Moreno, Santiago ^{[2
,16
]}

Garcia-Cosio, Monica ^{[2
,17
]}

Martin-Acosta, Paloma ^{[2
,18
]}

Garcia, Juan F. ^{[2
,19
]}

Planelles, Maria ^{[20
]}

Quero, Cristina ^{[21
]}

Provencio, Mariano ^{[22
]}

Mahillo-Fernandez, Ignacio ^{[23
]}

Rodriguez-Pinilla, Socorro M. ^{[1
,2
]}

Derenzini, Enrico ^{[24
]}

Pileri, Stefano ^{[24
]}

Sanchez-Beato, Margarita ^{[2
,25
]}

Cordoba, Raul ^{[2
,25
]}

Piris, Miguel A. ^{[1
,2
,26
]}

机构：

[1] IIS Hosp Univ Fdn Jimenez Diaz, Pathol Dept, Madrid, Spain

[2] Ctr Biomed Network Res Canc CIBERONC, ISCIII, Madrid, Spain

[3] Lymphoma Res Grp, IIS Puerta Hierro Segovia Arana IDIPHISA, Madrid, Spain

[4] Hosp Univ Puerto Real, UGC Labs, Cadiz, Spain

[5] Hosp Univ Doce Octubre, Pathol Dept, Madrid, Spain

[6] Hosp Alvaro Cunqueiro, Pathol Dept, Vigo, Spain

[7] Hosp Univ Bellvitge, Pathol Dept, Barcelona, Spain

[8] Hosp Duran & Reynals, Inst Catala Oncol, Haematol Dept, Barcelona, Spain

[9] Hosp Univ Getafe, Pathol Dept, Madrid, Spain

[10] Hosp Univ & Politecn La Fe, Pathol Dept, Valencia, Spain

[11] Hosp Univ La Paz, Pathol Dept, Madrid, Spain

[12] Hosp Univ La Paz, Haematol Dept, Madrid, Spain

[13] Hosp Univ Principe Asturias, Pathol Dept, Madrid, Spain

[14] IIS Hosp Univ Fdn Jimenez Diaz, Expt Hematol Lab, Madrid, Spain

[15] Univ Cordoba, Hosp Univ Reina Sofia, Maimonides Biomed Res Inst, Haematol Dept, Cordoba, Spain

[16] Hosp Univ Marques de Valdecilla, Pathol Dept, Santander, Spain

[17] Hosp Univ Ramon y Cajal, Pathol Dept, Madrid, Spain

[18] Hosp Univ Puerta Hierro, Pathol Dept, Madrid, Spain

[19] MD Anderson Canc Ctr, Pathol Dept, Madrid, Spain

[20] Hosp Gen Univ Alicante, Pathol Dept, Alicante, Spain

[21] Hosp Gen Univ Virgen de la Victoria, Complejo Hosp Costa Sol, Clin Oncol Dept, Marbella, Malaga, Spain

[22] Clin Oncol Dept, IIS Puerta Hierro Segovia Arana IDIPHISA, Madrid, Spain

[23] IIS Hosp Univ Fdn Jimenez Diaz, Dept Epidemiol, Madrid, Spain

[24] IEO European Inst Oncol IRCCS, Div Haematooncol & Haematopathol, Milan, Italy

[25] IIS Hosp Univ Fdn Jimenez Diaz, Haematol Dept, =, Madrid, Spain

[26] Hosp Univ Fdn Jimenez Diaz, Inst Invest Sanitaria Fdn Jimenez Diaz, Dept Pathol, Av Reyes Catolicos 2, E-28040 Madrid, Spain

来源：

EJHAEM | 2022年 / 3卷 / 03期

关键词：

DLBCL; gene expression; immunochemotherapy; diffuse large B-cell lymphoma; prognosis; RITUXIMAB PLUS CYCLOPHOSPHAMIDE; GENE-EXPRESSION; MOLECULAR CLASSIFICATION; R-CHOP; SURVIVAL; MYC; BCL2; RISK; PREDICTS; ORIGIN;

D O I：

10.1002/jha2.457

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Diffuse large B-cell lymphoma (DLBCL), the most frequent non-Hodgkin's lymphoma subtype, is characterized by strong biological, morphological, and clinical heterogeneity, but patients are treated with immunochemotherapy in a relatively homogeneous way. Here, we have used a customized NanoString platform to analyze a series of 197 homogeneously treated DLBCL cases. The platform includes the most relevant genes or signatures known to be useful for predicting response to R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) in DLBCL cases. We generated a risk score that combines the International Prognostic Index with cell of origin and double expression of MYC/BCL2, and stratified the series into three groups, yielding hazard ratios from 0.15 to 5.49 for overall survival, and from 0.17 to 5.04 for progression-free survival. Group differences were highly significant (p < 0.0001), and the scoring system was applicable to younger patients (<60 years of age) and patients with advanced or localized stages of the disease. Results were validated in an independent dataset from 166 DLBCL patients treated in two distinct clinical trials. This risk score combines clinical and biological data in a model that can be used to integrate biological variables into the prognostic models for DLBCL cases.

引用

页码：722 / 733

页数：12

共 50 条

[21] Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma
Kim, Eugene
Jiang, Yanwen
Xu, Tao
Bazeos, Alexandra
Knapp, Andrea
Bolen, Christopher R.
Humphrey, Kathryn
Nielsen, Tina G.
Penuel, Elicia
Paulson, Joseph N.
BMC CANCER, 2022, 22 (01)
[22] Muscle Loss During Immunochemotherapy for Diffuse Large B-Cell Lymphoma and its Clinical and Prognostic Associations
Lucijanic, Marko
Korunic, Renata Huzjan
Sedinic, Martina
Kusec, Rajko
Pejsa, Vlatko
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S376 - S376
[23] Advances in Multi-Omics Study of Prognostic Biomarkers of Diffuse Large B-Cell Lymphoma
Liang, Xiao-jie
Song, Xin-yu
Wu, Jia-lin
Liu, Dan
Lin, Bing-yu
Zhou, Hong-sheng
Wang, Liang
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2022, 18 (04): : 1313 - 1327
[24] Diffuse large B-cell lymphoma with MYC gene rearrangements Current perspective on treatment of diffuse large B-cell lymphoma with MYC gene rearrangements; case series and review of the literature
de Jonge, A. V.
Roosma, T. J. A.
Houtenbos, I.
Vasmel, W. L. E.
van de Hem, K.
de Boer, J. P.
van Maanen, T.
Lindauer-van der Werf, G.
Beeker, A.
Timmers, G. J.
Schaar, C. G.
Soesan, M.
Poddighe, P. J.
de Jong, D.
Chamuleau, M. E. D.
EUROPEAN JOURNAL OF CANCER, 2016, 55 : 140 - 146
[25] Diffuse large B-cell lymphoma - a new look and old prognostic factors
Dobrea, Camelia
Al Salamat, Hamed
Lupu, Anca Roxana
REVISTA ROMANA DE MEDICINA DE LABORATOR, 2012, 20 (04): : 307 - 315
[26] Prognostic Value of Histone Modifying Enzyme EZH2 in RCHOP-Treated Diffuse Large B-Cell Lymphoma and High Grade B-Cell Lymphoma
Petronilho, Sara
Sequeira, Jose Pedro
Paulino, Sofia
Lopes, Paula
Lisboa, Susana
Chacim, Sergio
Lobo, Joao
Teixeira, Manuel
Jeronimo, Carmen
Henrique, Rui
JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (12):
[27] Translating the Biology of Diffuse Large B-cell Lymphoma Into Treatment
Danilov, Alexey, V
Magagnoli, Massimo
Matasar, Matthew J.
ONCOLOGIST, 2022, 27 (01) : 57 - 66
[28] The Prognostic Impact of Comorbidities in Patients with De-Novo Diffuse Large B-Cell Lymphoma Treated with R-CHOP Immunochemotherapy in Curative Intent
Kocher, Florian
Mian, Michael
Seeber, Andreas
Fiegl, Michael
Stauder, Reinhard
JOURNAL OF CLINICAL MEDICINE, 2020, 9 (04)
[29] Serum level of CXCL10 is associated with inflammatory prognostic biomarkers in patients with diffuse large B-cell lymphoma
Hong, Jung Yong
Ryu, Kyung Ju
Lee, Ji Yean
Park, Chaehwa
Ko, Young Hyeh
Kim, Won Seog
Kim, Seok Jin
HEMATOLOGICAL ONCOLOGY, 2017, 35 (04) : 480 - 486
[30] Diffuse large B-cell lymphoma
Li, Shaoying
Young, Ken H.
Medeiros, L. Jeffrey
PATHOLOGY, 2018, 50 (01) : 74 - 87

← 1 2 3 4 5 →